| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Theravance Biopharma, Inc.$16.93
-0.05 (-0.29%)
C 59Pipeline Score Undervalued Pharma · Commercial
Market Cap
843.92 M
EPS
2.27
P/E Ratio
7.43 $
Value Trade
5.32 M
SEC Financials
Q1 2026Dilution Risk
Revenue
17.70 M
R&D Expenses
5.83 M
Operating CF
73.28 M
Total Assets
472.31 M
Total Liabilities
472.31 M
Equity
290.59 M
D/E Ratio
12,345
-0.73 %
Week
-2.09 %
1 Month
-15.71 %
3 Month
-7.88 %
6 Month
-8.95 %
5 Year
10.98 %
All Time
Cash Data
Cash Position
394.67 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
868.56 K
52 Week Range
9.10 - 21.03
% held by Insiders
6.46 %
% held by Institutions
95.48 %
Enterprise Value
522.56 M
Total Shares
51.55 M
Short %
9.55 %
Float Shares
47.17 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Theravance Biopharma, Inc.
673Total events
2Upcoming
194Tier-1 (high impact)
2015 – 2026Coverage
Upcoming catalysts 2
Event history 671
Q3 2026
◆AcquiredCorporate
Theravance Biopharma to be acquired by Zymeworks for $17.00 per share plus CVR
Q3 2026
▲Runway Guidance UpdateCorporate
Full run-rate cost savings of ~$70M expected to materialize in Q3 2026
Q3 2026
●Timing GuidancePresentation
Full run-rate cost savings of ~$70M expected to materialize in Q3 2026
Q2 2026
●Timing GuidancePresentation
Restructuring actions expected to be implemented over next two quarters
Mar 19, 2026
Mar 3, 2026
◆Topline ReadoutAmpreloxetineClinical Data
Topline results from ampreloxetine Phase 3 CYPRESS study announced
Multiple System Atrophy (MSA) and neurogenic orthostatic hypotension (nOH)source ↗
Mar 3, 2026
▼Program DiscontinuationAmpreloxetineCorporate
Wind down of ampreloxetine program
symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA)source ↗
Mar 3, 2026
▼Restructuring LayoffsCorporate
Organizational restructuring impacting ~50% of workforce; wind down of R&D and reduction in G&A
Mar 3, 2026
▼Primary Endpoint MissedAmpreloxetineClinical Data
Phase 3 CYPRESS study did not meet primary endpoint (OHSA composite score)
symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA)source ↗
Mar 3, 2026
◆Timing GuidancePresentation
Strategic review accelerated; evaluating alternatives including sale of company
Drug Pipeline Intelligence
C59
Pipeline Score $3.2B
Pipeline ValueUndervalued
Valuation Signal27
Drugs Scored3.8x
rNPV / MCap Top 86%
Micro Cap (rank 129 of 911)
Percentile RankTheravance Biopharma, Inc. carries a moderate pipeline score (59/100), with $7.9B risk-adjusted pipeline value, led by Telavancin in Infection (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Telavancin Small molecule | Infection | Phase 2 | NCT01321879 | 27% | $2.0B | COMPLETED | 40 | - | - | Dec 1, 2016 | - | Dec 27, 2019 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ampreloxetine Orphan | symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy | Phase 3 | 2025-10-29 | increase in norepinephrine levels, a favorable impact on blood pressure, clinically meaningful and durable symptom improvement, and no signal for worsening of supine hypertension Read More | Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System Read More | |
ampreloxetine Orphan | symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy | Phase 3 | 2025-10-29 | increase in norepinephrine levels, a favorable impact on blood pressure, clinically meaningful and durable symptom improvement, and no signal for worsening of supine hypertension Read More | Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System Read More | |
ampreloxetine Orphan | symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy | Phase 3 | 2025-10-29 | increase in norepinephrine levels, a favorable impact on blood pressure, clinically meaningful and durable symptom improvement, and no signal for worsening of supine hypertension Read More | Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TBPH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TBPH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TBPHTHERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
Theravance Biopharma has entered into a definitive agreement to be acquired by Zymeworks for $17.00 per share, totaling approximately $929 million. Shareholders will also receive a contingent value right entitling them to 80% of future proceeds from ampreloxetine. The transaction is expected to close in the second half of 2026, pending shareholder approval and regulatory conditions.
Read more →TBPHTheravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update YUPELRI® Collaboration Revenue increased 15% year-over-year1, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved...
Theravance Biopharma reported a 15% increase in YUPELRI collaboration revenue for Q1 2026, reaching $17.7 million. The company has successfully resolved all Hatch-Waxman litigation related to YUPELRI and achieved a 20% reduction in operating expenses. Despite a net loss of $4.9 million, Theravance maintains a strong cash position of $395 million and is confident in reaching a $100 million milestone payment from TRELEGY sales.
Read more →TBPHTheravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update YUPELRI Collaboration Revenue increased 15% year-over-year 1 , from $15.4 million to $17.7 million, driven by continue
Theravance Biopharma reported strong financial results for Q1 2026, highlighting a 15% increase in YUPELRI revenue. The company's strategic restructuring aims to reduce operating expenses significantly while maintaining profitability. However, the underwhelming results of the CYPRESS study pose challenges. The Board is exploring strategic alternatives, which may include a potential sale of the company, reflecting ongoing uncertainty in their operational focus.
Read more →TBPHTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of
Theravance Biopharma, Inc. reported its fourth quarter and full year 2025 financial results, achieving a record non-GAAP profitability. The company highlighted the success of YUPELRI and announced a significant corporate restructuring plan aimed at reducing costs and aligning resources, projected to save approximately $70 million annually. Despite these positive financial results, the CYPRESS study did not meet its primary endpoint, prompting the organization to wind down its R&D function and cut half of its workforce over the next quarters.
Read more →TBPH▼ -26.3%on this news
Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions
Theravance Biopharma announced that its Phase 3 CYPRESS study of ampreloxetine failed to meet its primary endpoint, leading to the decision to wind down the program. In response, the company is accelerating its strategic review and implementing significant cost reductions, including a workforce reduction of about 50%. Despite these setbacks, Theravance maintains a strong cash position and expects to generate substantial cash flow from its existing product, YUPELRI.
Read more →TBPH▼ -26.3%on this newsshared move
E xhibit 99.1 Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions Phase 3 CYPRESS study did not meet the primary endpo
Theravance Biopharma announced that its Phase 3 CYPRESS study did not meet the primary endpoint, leading the company to wind down the ampreloxetine program. In response, Theravance's Board is accelerating a strategic review and implementing significant cost reductions, expecting to cut operating expenses by about 60%. Despite this setback, the company remains optimistic about YUPELRI's performance and has a healthy cash balance projected at $400 million by Q1 2026, along with the potential for a $100 million milestone payment from TRELEGY.
Read more →TBPHTHERAVANCE BIOPHARMA , THERAVANCE , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third -
Theravance Biopharma has issued a presentation outlining forward-looking statements regarding its business strategies and future expectations. The company emphasized its goals for profitability and cash generation, particularly from YUPELRI sales, and discussed upcoming data for its investigational therapy, Ampreloxetine. However, it acknowledged various risks that could impact its financial health and clinical progress, including uncertainties associated with cash requirements and regulatory decision-making.
Read more →TBPHTheravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025
Theravance Biopharma will host a virtual KOL investor event on December 8, 2025, to discuss the Phase 3 CYPRESS study of ampreloxetine for neurogenic orthostatic hypotension in multiple system atrophy patients. Dr. Horacio Kaufmann will present the unmet medical need and the study's strategic design. The event will also cover ampreloxetine's commercial potential.
Read more →TBPHTheravance Biopharma to Participate in Upcoming Investor Conferences
Theravance Biopharma will participate in two investor conferences in December 2025, including the Evercore Healthcare Conference and the Oppenheimer Movers in Rare Disease Summit. The company will also be available for one-on-one meetings with investors. A live webcast of the Evercore presentation will be accessible on their website, with a replay available for 30 days.
Read more →TBPH▲ +22.7%on this news
Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Theravance Biopharma reported strong financial results for Q3 2025, with record net sales for YUPELRI and achieving non-GAAP breakeven. The company also highlighted progress in the pivotal Phase 3 CYPRESS study for ampreloxetine, aimed at treating neurogenic orthostatic hypotension in patients with multiple system atrophy. The CEO expressed confidence in the company's financial position and upcoming milestones.
Read more →TBPHTheravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System
Theravance Biopharma will present data on ampreloxetine at the 36th International Symposium on the Autonomic Nervous System. The presentations will include a platform presentation and three posters focusing on the drug's efficacy for neurogenic orthostatic hypotension in patients with multiple system atrophy. The company aims to highlight the positive outcomes from previous trials and share insights on clinical trial methodologies.
Read more →TBPHTheravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on...
Theravance Biopharma, Inc. plans to report its third quarter 2025 financial results and offer a business update on November 10, 2025, after market close. A conference call will follow at 5:00 PM EST, allowing participants to engage in the discussion. The company, known for its focus on impactful medicines, has previously developed FDA-approved treatments and is working on new therapies for conditions such as neurogenic orthostatic hypotension. A replay of the webcast will be accessible for 30 days post-event.
Read more →TBPHTheravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
Theravance Biopharma announced it will present new analyses on YUPELRI at the 2025 CHEST Annual Meeting. The findings indicate that patients adhering to YUPELRI experienced significantly fewer exacerbations and lower healthcare costs compared to non-adherent patients. Additionally, the data suggest YUPELRI's efficacy is comparable to tiotropium, reinforcing its role in COPD management.
Read more →TBPHTheravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Theravance Biopharma, Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference in New York City. CEO Rick Winningham will engage in a Fireside Chat on September 9, 2025. The company will also host in-person meetings for interested investors. A live webcast of the event will be available on their website.
Read more →TBPHTheravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
Theravance Biopharma has completed enrollment in the Phase 3 CYPRESS study, which evaluates ampreloxetine for treating symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). This study aims to assess the efficacy and safety of ampreloxetine, which targets the underlying cause of nOH. Topline data is expected in Q1 2026, with plans for an expedited NDA submission if results are favorable.
Read more →TBPHTheravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update YUPELRI (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year 1 Pivotal Phase
Theravance Biopharma, Inc. announced its financial results for the second quarter of 2025, highlighting a 22% increase in YUPELRI (revefenacin) net sales year-over-year. The company benefited from a $7.5 million milestone payment linked to YUPELRI's recent approval in China and secured $225 million from the monetization of its TRELEGY royalty interest. Moving forward, Theravance is focused on ampreloxetine, with plans to complete enrollment for its pivotal Phase 3 CYPRESS study by late summer 2025, anticipating top-line data six months thereafter.
Read more →TBPHTheravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the second...
Theravance Biopharma reported a strong second quarter in 2025, with YUPELRI net sales reaching $66.3 million, a 22% increase from the previous year. The company completed the sale of its TRELEGY royalty interest for $225 million, enhancing its financial position. Enrollment for the pivotal Phase 3 CYPRESS study for ampreloxetine is nearing completion, with top-line data expected in six months. Despite a positive outlook, the company reported a non-GAAP net loss of $4.2 million.
Read more →TBPHTheravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025
Theravance Biopharma, Inc. is set to report its second quarter 2025 financial results on August 12, 2025. The announcement includes a conference call scheduled for the same day at 5:00 pm ET. The company aims to provide a business update alongside its financial performance. Theravance is known for its commitment to developing impactful medicines, including its FDA-approved product YUPELRI and the investigational drug Ampreloxetine.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30 at...
Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the BTIG Virtual Biotechnology Conference on July 30, where senior management will host a fireside chat. In addition, management will be available for one-on-one meetings to discuss company developments and objectives with investors. The company's commitment to creating and driving shareholder value through innovative biopharmaceutical solutions is emphasized, notably with their FDA-approved YUPELRI and investigational treatments.
Read more →TBPHTheravance Biopharma Announces Approval of YUPELRI (revefenacin) by China's NMPA YUPELRI approved by China's NMPA as the first once-daily nebulized LAMA for maintenance treatment of COPD Approval triggers $7.5 million mi
Theravance Biopharma has announced that YUPELRI (revefenacin) has been approved by China's National Medical Products Administration (NMPA) as the first once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease (COPD). This approval triggers a $7.5 million milestone payment from Viatris Inc. to Theravance, with additional potential sales-based milestones and royalties. The news reflects positively on Theravance's financial outlook, bolstered by cash reserves and ongoing clinical trials for other treatments, including ampreloxetine for neurogenic orthostatic hypotension associated with multiple system atrophy.
Read more →TBPHTheravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that Viatris Inc. ("Viatris"), has secured...
Theravance Biopharma announced that YUPELRI (revefenacin) has received approval from China's NMPA as the first once-daily nebulized LAMA for COPD maintenance treatment. This approval will result in a $7.5 million milestone payment from Viatris, which is also responsible for the commercialization in China. Additionally, Theravance stands to gain further sales milestones and royalties from YUPELRI sales.
Read more →TBPH▲ +21.7%on this news
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $15
Theravance Biopharma has completed the sale of its remaining royalty interest in Trelegy Ellipta to GSK for $225 million in cash. This agreement, along with previous transactions, underscores the company's strategy to maximize shareholder value through effective capital management and monetization efforts. The company retains rights to additional potential milestone payments totaling up to $150 million based on future Trelegy sales performance, indicating confidence in the product's ongoing success. The transaction is positioned as a key outcome of the Strategic Review Committee's evaluations and efforts.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New ...
Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City on May 20, 2025. The event aims to engage with the investment community and will also feature a webcast available on their website. The company is known for its COPD treatment YUPELRI and is developing Ampreloxetine for neurogenic orthostatic hypotension, enhancing its commitment to shareholder value.
Read more →TBPH▼ -9.3%on this newsshared move
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3...
Theravance Biopharma announced the presentation of analyses from its Phase 3 program for ampreloxetine at the International MSA Congress. The analyses focused on the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), demonstrating a substantial symptom burden despite existing treatments. The results bolster the ongoing registrational study, CYPRESS, which aims to further investigate the efficacy of ampreloxetine in this patient population.
Read more →TBPHTheravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update YUPELRI (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 2024 1 TRELEGY net sal
Theravance Biopharma, Inc. reported a solid financial performance for Q1 2025, with YUPELRI net sales growing by 6% year-over-year to reach $58.3 million. The company highlighted its strong commercial partnership with Viatris, which is managing YUPELRI's market presence. The ongoing Phase 3 CYPRESS study for ampreloxetine, aimed at treating symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy, is nearing enrollment completion. The company remains focused on strategies to enhance shareholder value through its Strategic Review Committee.
Read more →TBPHTheravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first...
Theravance Biopharma reported its Q1 2025 financial results, highlighting a 6% increase in YUPELRI sales and a strong cash position of $131 million. The CYPRESS study for ampreloxetine is nearing completion, with top-line data expected in about six months. However, the company also noted an increase in net loss and rising expenses in R&D and SG&A compared to the previous year.
Read more →TBPHTheravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of...
Theravance Biopharma has announced that analyses from its Phase 3 program of ampreloxetine will be presented at the International MSA Congress in May 2025. These findings aim to clarify ampreloxetine's mechanism and its potential to alleviate symptoms of neurogenic orthostatic hypotension in patients with multiple system atrophy. Despite prior challenges, including unmet primary endpoints in specific patient populations, the company remains optimistic about ongoing studies and the upcoming data presentation.
Read more →TBPHTheravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on...
Theravance Biopharma, Inc. plans to announce its first quarter 2025 financial results on May 8, 2025, following market close. The announcement will be accompanied by a conference call and webcast to discuss the results and provide a business update. Theravance continues to develop its pipeline, including FDA-approved medications and investigational treatments, highlighting its commitment to improving patient care.
Read more →TBPHTheravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced new analyses from its previous Phase 3 program...
Theravance Biopharma recently presented analyses from its Phase 3 program for ampreloxetine at the American Academy of Neurology conference. The results indicate that ampreloxetine has a favorable safety profile and effectively engages its target mechanism without worsening supine hypertension. However, while positive outcomes were observed in patients with multiple system atrophy (MSA), the primary endpoint for one trial was not achieved, raising questions about the broader efficacy of the treatment. The company is currently pursuing further studies to solidify ampreloxetine's potential in treating symptomatic neurogenic orthostatic hypotension.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las...
Theravance Biopharma, Inc. (TBPH) is participating in the Jones Healthcare and Technology Innovation Conference in Las Vegas, scheduled for April 9. Senior management will hold one-on-one meetings and a fireside chat during the event. The company plans to provide a recording of the event for those who cannot attend. Theravance focuses on creating impactful medicines, including its FDA-approved product for COPD and a late-stage investigational therapy for neurogenic orthostatic hypotension.
Read more →TBPHTheravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of...
Theravance Biopharma, Inc. has announced new analyses of ampreloxetine for neurogenic orthostatic hypotension (nOH) to be presented at the upcoming 77th Annual Meeting of the American Academy of Neurology. These analyses will support ampreloxetine's differentiated pharmacodynamic profile and its potential effectiveness in treating symptoms associated with multiple system atrophy. Despite earlier studies not meeting their primary endpoints, the company remains committed to advancing its research, capitalizing on the ongoing Phase 3 CYPRESS study to potentially secure full approval for the drug.
Read more →TBPHTheravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results YUPELRI (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 mil
Theravance Biopharma, Inc. reported its financial results for the fourth quarter and full year of 2024, revealing record net sales of $66.7 million for YUPELRI (revefenacin). The company's partnership with Viatris has been fruitful, particularly in the commercialization of YUPELRI. Additionally, Theravance achieved significant milestones related to TRELEGY sales, receiving $50 million in royalty payments. The company is making strides in its pivotal CYPRESS Study and remains focused on shareholder value enhancement.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 11:50 am EST (8:50...
Theravance Biopharma, Inc. (NASDAQ: TBPH) is set to present at the TD Cowen 45th Annual Health Care Conference on March 4 at 11:50 am EST. The company will also hold in-person meetings with the investment community during this event. Theravance is known for its FDA-approved therapeutic offerings, including YUPELRI, and is developing promising drugs like Ampreloxetine for treating neurogenic orthostatic hypotension in Multiple System Atrophy patients.
Read more →TBPHTheravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after...
Theravance Biopharma, Inc. is set to report its fourth quarter and full year 2024 financial results on February 26, 2025. A conference call and webcast will follow the market close to discuss the results and provide a business update. The company is known for its FDA-approved drug YUPELRI for COPD and is developing a new therapy, Ampreloxetine, aimed at treating MSA-related symptoms. This event reflects the company's commitment to transparency and shareholder engagement.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12...
Theravance Biopharma, Inc. (NASDAQ: TBPH) is set to present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025. The event will feature a live webcast available on their website, with a recorded replay accessible for 30 days. Theravance focuses on developing innovative treatments, notably with their FDA-approved YUPELRI and the investigational drug ampheloxetine for neurogenic orthostatic hypotension in Multiple System Atrophy patients.
Read more →TBPHTheravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced that members of its management team will hold...
Theravance Biopharma, Inc. has announced its plans to hold investor meetings during the upcoming 43rd Annual J.P. Morgan Healthcare Conference scheduled from January 13-16, 2025, in San Francisco, CA. The management team will participate in these meetings to discuss the company's recent developments and future prospects. Theravance is known for its commitment to creating impactful medicines, such as its FDA-approved YUPELRI and the investigational Ampreloxetine. These engagements highlight the company's focus on driving shareholder value.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 ...
Theravance Biopharma, Inc. (NASDAQ: TBPH) is set to participate in the 7th Annual Evercore HealthCONx Conference on December 3. The event will feature a Fireside Chat at 11:15 am EST and provide opportunities for in-person meetings with investors. The company focuses on delivering impactful medicines, with its pipeline including FDA-approved therapies and late-stage investigational products aimed at addressing specific medical conditions.
Read more →TBPHTheravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million,...
Theravance Biopharma reported strong operational performance for Q3 2024, with YUPELRI net sales reaching $62.2 million, a 7% increase from Q3 2023. The company is on track with CYPRESS enrollment and has formed a Strategic Review Committee to explore options for unlocking shareholder value. However, it also reported a net loss of $12.7 million and incurred a non-cash impairment charge.
Read more →TBPHTheravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value Third quarter results highlight strong operational performance across key value drivers: o YUP
Theravance Biopharma, Inc. has reported its financial results for the third quarter of 2024, highlighting record sales for its product YUPELRI. The company announced the establishment of a Strategic Review Committee to explore avenues for maximizing shareholder value. Additionally, they reaffirmed their development timelines for the CYPRESS study, which involves the investigational therapy ampreloxetine for neurogenic orthostatic hypotension. Overall, the results showcase a strong operational performance and strategic positioning moving forward.
Read more →TBPHTheravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2024 financial results and provide a business update after market close on...
Theravance Biopharma, Inc. (NASDAQ: TBPH) will be reporting its third quarter 2024 financial results and a business update on November 12, 2024. The announcement includes details about a conference call scheduled for the same day, which will provide investors with insights into the company’s performance. The company emphasizes its commitment to delivering impactful medicines, such as YUPELRI and the investigational drug Ampreloxetine. Information regarding the conference call can be found on their official website.
Read more →TBPHTheravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced the publication of a sub-study of the pivotal...
Theravance Biopharma announced the publication of a sub-study analyzing its drug YUPELRI (revefenacin) in the treatment of chronic obstructive pulmonary disease (COPD). This research, published in the International Journal of Chronic Obstructive Pulmonary Disease, suggests that YUPELRI offers consistent, long-lasting benefits in lung function. Experts indicated that the drug shows rapid bronchodilation effects and lasting efficacy over a 24-hour period, reinforcing its clinical importance in managing COPD symptoms.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New...
Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City on September 10, 2024. The company will also host in-person meetings with investors during the conference. Interested parties can access a webcast of the event on Theravance's website, which will be available for replay for 30 days. The company's focus includes delivering innovative medicines, particularly their investigational drug ampreloxetine for neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
Read more →TBPHTheravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 20231 Viatris collaboration revenue of $14.3...
Theravance Biopharma, Inc. reported its second quarter financial results for 2024, with YUPELRI net sales decreasing by 1% compared to the previous quarter. CEO Rick Winningham expressed disappointment but maintained optimism for YUPELRI's future growth, attributing the sales decline to market factors. The company is advancing its clinical study for ampreloxetine, expecting to enroll the last patient by mid-2025. Notably, the company reported positive developments for TRELEGY, boosting its confidence in meeting 2024 milestones.
Read more →TBPHTheravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update Q2 2024 YUPELRI (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 2023 1 Viatris c
Theravance Biopharma, Inc. reported its financial and operational results for Q2 2024, highlighting a 1% decrease in YUPELRI net sales compared to the previous quarter. CEO Rick Winningham expressed disappointment with the sales results but noted confidence in future growth due to strong demand. The company activated over 80% of study sites for the CYPRESS trial, aiming to enroll the last patient by mid-2025. Additionally, they reported a successful quarter for TRELEGY, contributing to internal financial strength.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 6 at...
Theravance Biopharma, Inc. (NASDAQ: TBPH) announced its participation in the BTIG Virtual Biotechnology Conference scheduled for August 6, 2024. Senior management will engage in one-on-one meetings and a fireside chat during the event. The conference is an opportunity for the company to highlight its achievements, including the FDA-approved medication YUPELRI and the investigational treatment Ampreloxetine. This engagement reflects the company's ongoing commitment to shareholder value and showcasing its innovative therapies.
Read more →TBPH▲ +7%on this newsshared move
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update after market close on...
Theravance Biopharma, Inc. (NASDAQ: TBPH) has announced it will report its second quarter 2024 financial results on August 5, 2024, after market close. The company plans to host a conference call and webcast regarding this update at 5:00 pm ET on the same day. Theravance Biopharma specializes in developing therapies like the FDA-approved YUPELRI for COPD and has a late-stage candidate, Ampreloxetine, for neurogenic orthostatic hypotension. A replay of the webcast will be accessible for 30 days on its website following the event.
Read more →TBPHTheravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Q1 2024 YUPELRI (revefenacin) net sales of $55.2 million, recognized by Viatris, increased 18% from Q1 2023 1 Viatris c
Theravance Biopharma, Inc. reported a strong financial performance for Q1 2024, highlighting net sales for YUPELRI of $55.2 million, an 18% increase from the previous year. The collaboration with Viatris also saw a substantial revenue growth of 39%. Additionally, the company is making progress with its investigational drug ampreloxetine, and a KOL event is scheduled for May 23, 2024, to discuss updates on it. The financial results and ongoing projects bolster confidence in Theravance's prospects for future growth.
Read more →TBPHTheravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the first...
Theravance Biopharma reported a strong first quarter for 2024 with YUPELRI net sales reaching $55.2 million, an 18% increase from the previous year. The company's collaboration revenue with Viatris also saw a significant rise of 39%. However, despite these positive financial indicators, Theravance experienced a net loss of $11.7 million, although this was an improvement compared to the same period last year. The company continues to focus on the growth of YUPELRI and the ongoing CYPRESS study for ampreloxetine.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at...
Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference scheduled for May 20, 2024. The event will include in-person meetings with the investment community, providing an opportunity for dialogue about the company’s projects and performance. Additionally, a webcast of the event will be accessible through the company's website, with replay available for 30 days.
Read more →TBPHTheravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on...
Theravance Biopharma, Inc. (NASDAQ: TBPH) is set to report its first quarter 2024 financial results on May 13, 2024, after the market closes. A conference call will accompany this report, providing a platform for investors to receive updates about the company. The webcast will be available for 30 days after the report on the company's website. Theravance focuses on innovative medicines, including their approved product YUPELRI and the investigational drug Ampreloxetine, aimed at treating symptoms in certain patient populations.
Read more →TBPHTheravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 Theravance Biopharma, Inc. (the Company ) (NASDAQ: TBPH) today announced it will host a virtual KOL event on Thursday, May 23, 2024 from 10:00 AM to ...
Theravance Biopharma, Inc. announced a virtual Key Opinion Leader (KOL) event scheduled for May 23, 2024, to discuss ampreloxetine's potential in treating symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). Esteemed experts such as Dr. Horacio Kaufmann and Dr. Italo Biaggioni will share insights on the treatment landscape and the unmet needs of MSA patients. The event will focus on Theravance's ongoing clinical development program for ampreloxetine, which is an investigational norepinephrine reuptake inhibitor.
Read more →TBPHTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Q4 2023 YUPELRI (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an a
Theravance Biopharma, Inc. reported its financial results for Q4 2023 and the full year, highlighting a 9% increase in net sales of YUPELRI, driven by Viatris's commercialization efforts. The company aims to complete enrollment in its CYPRESS study for ampreloxetine, targeting symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. Additionally, Theravance has entered settlement agreements regarding ongoing patent litigation, which allow for the potential introduction of generic versions of YUPELRI in the future. Despite these positive developments, the company faces competition as legal disputes with other ANDA filers remain unresolved.
Read more →TBPHTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the fourth...
Theravance Biopharma reported strong financial results for Q4 and full-year 2023, with YUPELRI net sales increasing 9% to $60.6 million. The company achieved a Non-GAAP net profit of $1.4 million, despite a GAAP net loss of $8.5 million. They completed a $325 million capital return program and received Orphan Drug Designation for ampreloxetine, which is in Phase 3 trials. The company looks forward to continued growth in 2024.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the CNS Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference...
Theravance Biopharma, Inc. will participate in the CNS Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference in Boston on March 5, 2024. Senior management will host one-on-one meetings with investors during this event. A live webcast of the panel discussion will be available on the company's website, followed by an archived replay for 30 days. This participation underscores Theravance's commitment to engaging with the investment community.
Read more →TBPHTheravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2023 financial results and provide a business update after...
Theravance Biopharma, Inc. will report its fourth quarter and full year financial results for 2023 on February 26, 2024. The announcement will be accompanied by a conference call and webcast for interested shareholders and analysts. The company is working on innovative treatments such as YUPELRI and the investigational drug Ampreloxetine, contributing to its commitment to creating shareholder value.
Read more →TBPH▼ -10%on this news
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the...
Theravance Biopharma announced results from the Phase 4 PIFR-2 study of YUPELRI, which aimed to compare its efficacy against Spiriva in patients with severe COPD. The study did not show a statistically significant difference in lung function improvement between the two treatments. However, YUPELRI maintained a safety profile consistent with earlier studies, and the company sees growth opportunities ahead.
Read more →TBPH▼ -10%on this news
Theravance Biopharma Announces Results from the Phase 4 YUPELRI PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) DUBLIN
Theravance Biopharma announced results from its Phase 4 PIFR-2 study of YUPELRI, a once-daily inhalation solution for COPD. While the study did not meet its primary endpoint, YUPELRI showed an efficacy and safety profile consistent with past studies. The company anticipates future growth opportunities and plans to share further data analyses regarding YUPELRI. The results highlight the ongoing demand for nebulized delivery options among COPD patients.
Read more →TBPHPage 1 of 3 Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Sha
Theravance Biopharma, Inc. has appointed Jeremy Grant to its Board of Directors as part of a continued effort to strengthen its governance and align with shareholder interests. The company has reached a cooperation agreement with Irenic Capital Management, which includes commitments from both parties aimed at enhancing shareholder value. Theravance has also reiterated its plans to return excess capital to shareholders, emphasizing a disciplined approach to financial management. This strategic shift comes as the board prepares for upcoming changes, including the departure of Dr. Burton Malkiel at the 2024 Annual General Meeting.
Read more →TBPHTheravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors Theravance Biopharma, Inc. ( Theravance or the Company ) (NASDAQ: TBPH) today announced the appointment to its Board of Directors of Jeremy Grant,...
Theravance Biopharma, Inc. has announced the appointment of Jeremy Grant to its Board of Directors, marking the fourth new director added since 2020. This appointment aligns with the company's ongoing strategy to enhance board diversity and strengthen governance. Additionally, Theravance has entered into a cooperation agreement with Irenic Capital, committing to a disciplined approach in maximizing shareholder value. The company has successfully returned over $300 million to shareholders while reducing shares outstanding and eliminating debt.
Read more →TBPHTheravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced that members of its management team including...
Theravance Biopharma, Inc. will hold investor meetings at the 42nd Annual J.P. Morgan Healthcare Conference from January 8-11, 2024, in San Francisco. Key management members, including CEO Rick E Winningham and CFO Aziz Sawaf, will participate in these meetings. The company continues to focus on delivering impactful medicines, including its FDA-approved drug, YUPELRI, and its late-stage investigational drug, Ampreloxetine. This initiative reflects their commitment to creating shareholder value.
Read more →TBPHTheravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced that a new, anchor-based analysis of...
Theravance Biopharma has announced that new data on ampreloxetine will be presented at the 34th International Symposium on The Autonomic Nervous System. This anchor-based analysis highlights its clinical relevance for treating neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). The findings suggest that ampreloxetine could offer significant benefits over placebo, focusing on clinically meaningful changes in patient outcomes. The company plans to further leverage this data in ongoing studies and future regulatory submissions.
Read more →TBPHTheravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update Q3 2023 YUPELRI (revefenacin) net sales, recognized by Viatris, increased 9% from Q3 2022, reaching an all-time high of
Theravance Biopharma, Inc. announced its Q3 2023 financial results, highlighting a 9% increase in net sales of YUPELRI, reaching an all-time high. The company reported a limited non-GAAP loss, indicating improved financial performance. Additionally, Theravance is progressing with its Phase 3 CYPRESS study for ampreloxetine, targeting symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. However, ongoing patent litigation and leadership transitions could pose operational challenges.
Read more →TBPHTHERAVANCE BIOPHARMA , THERAVANCE , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third p
Theravance Biopharma has outlined its strategic objectives aimed at driving value creation as it continues to focus on its product YUPELRI. The company reported a 12% increase in net sales during Q2 2023 compared to the same quarter in the previous year, alongside a 45% rise in hospital doses. Theravance is working towards ensuring the success of its open market share repurchase program and aims to enhance the growth trajectory of YUPELRI, while addressing financial measures and operational efficiencies.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference on...
Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023. The company will host in-person meetings with investors and provide a webcast of the event accessible via their website. Theravance focuses on delivering innovative medicines, including FDA-approved therapies for chronic obstructive pulmonary disease and investigational treatments in development.
Read more →TBPHTheravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic...
Theravance Biopharma announced the presentation of new data regarding ampreloxetine for neurogenic orthostatic hypotension at the 2023 International Congress of Parkinson's Disease and Movement Disorders. The data suggest that ampreloxetine may offer significant benefits for patients with multiple system atrophy, particularly in improving symptoms related to blood pressure control. However, while the treatment demonstrates a favorable safety profile, the primary endpoint of a related study was not statistically significant for the overall patient population, leading to concerns regarding its efficacy. Theravance remains committed to pursuing regulatory approval based on ongoing studies.
Read more →TBPHTheravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 20221 Q2 2023 YUPELRI total retail TRx and new to...
Theravance Biopharma reported strong growth in YUPELRI sales, achieving $55 million in Q2 2023, a 12% increase from the previous year. The company anticipates completing the PIFR-2 study with results expected in January 2024. Despite a net loss of $15.6 million, Theravance aims for non-GAAP profitability in the second half of 2023, supported by increased sales growth.
Read more →TBPHTheravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update Q2 2023 YUPELRI (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 2022 1 Q2 2023 YUPELRI
Theravance Biopharma, Inc. announced its financial results for the second quarter of 2023, highlighting a 12% increase in YUPELRI (revefenacin) net sales compared to the previous year. The company plans to complete enrollment in the YUPELRI PIFR-2 study soon, with anticipated top-line data by January 2024. Despite optimism around profitability in H2 2023, there are concerns related to dependency on Viatris for commercialization and risks linked to achieving financial milestones. Overall, the company continues to work to enhance its market presence in chronic obstructive pulmonary disease (COPD) treatment.
Read more →TBPHTheravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2023 financial results and provide a business update after market close on...
Theravance Biopharma, Inc. (NASDAQ: TBPH) is set to report its second quarter 2023 financial results on August 7, 2023, after market close. The company will also conduct a conference call and webcast at 5:00 PM ET to discuss the results and provide a business update. Investors can access the live call via telephone or internet, with a replay available on their website for 30 days post-event. Theravance is known for its commitment to developing essential medicines, including treatments for chronic obstructive pulmonary disease (COPD).
Read more →TBPHTheravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced that the US Food and Drug Administration (FDA)...
Theravance Biopharma, Inc. announced that the FDA has granted Orphan Drug Designation to its investigational drug ampreloxetine for treating symptomatic neurogenic orthostatic hypotension (nOH) in patients suffering from multiple system atrophy (MSA). This designation aims to facilitate the development of treatments for rare diseases. The company cited the significant impact this drug could have on the quality of life for patients and stated that they are advancing their Phase 3 study, CYPRESS, as part of their commitment to bringing the therapy to market. Ampreloxetine has demonstrated efficacy in previous clinical trials, highlighting its potential benefits for this patient population.
Read more →TBPHTheravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update Q1 2023 YUPELRI (revefenacin) net sales of $47.0 million, recognized by Viatris, up 8% from Q1 2022 1 Q1 2023 YUPELRI r
Theravance Biopharma, Inc. reported its first-quarter 2023 financial results, noting $47 million in net sales for YUPELRI, an 8% increase from the previous year. CEO Rick E Winningham highlighted a 61% growth in new patient starts and indicated that the company has successfully initiated enrollment for the Phase 3 CYPRESS study for ampreloxetine. The firm also addressed a $2.8 million revenue decrease due to a prior-year milestone payment. Despite these challenges, they are optimistic about YUPELRI's value and commitment to shareholder returns.
Read more →TBPHTheravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2023 financial results and provide a business update after market close on...
Theravance Biopharma, Inc. (NASDAQ: TBPH) is scheduled to report its first quarter 2023 financial results and provide a business update on May 8, 2023, after market close. The event will be accompanied by a conference call and webcast at 5:00 pm ET. The company continues to leverage its expertise in drug development, notably with its FDA-approved YUPELRI and its innovative investigational drug, Ampreloxetine, aimed at treating neurogenic orthostatic hypotension.
Read more →TBPHTheravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced the appointment of Jim Kelly, Managing Director...
Theravance Biopharma, Inc. has appointed Jim Kelly, Managing Director at Weiss Asset Management, to its Board of Directors. Kelly's extensive investment experience and understanding of the healthcare industry are seen as valuable assets as the company seeks to maximize shareholder value. This appointment is part of an ongoing board refreshment initiative, with four new directors joining since 2018. The company aims to drive growth and returns for its shareholders through strategic governance and collaboration.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17 at 3:45 pm ET...
Theravance Biopharma, Inc. will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023. The event will be accessible via webcast on the company's website, where it will also be available for replay for 30 days. Theravance emphasizes its mission to develop impactful medicines, including the FDA-approved treatment YUPELRI for COPD and an investigational therapy for neurogenic orthostatic hypotension. The company aims to enhance shareholder value through its initiatives.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the Respiratory/Infections Corporate Panel Discussion at the 43rd Annual TD Cowen...
Theravance Biopharma, Inc. (NASDAQ: TBPH) is scheduled to participate in the Respiratory/Infections Corporate Panel Discussion at the 43rd Annual TD Cowen Health Care Conference on March 8, 2023. The event will include a webcast available on the company's website, promoting transparency and accessibility for investors. Theravance focuses on developing impactful medications, including FDA-approved treatments for chronic obstructive pulmonary disease and investigational therapies for other conditions. The company aims to drive shareholder value while advancing its product pipeline.
Read more →TBPHContinued Transformation Positions Theravance Biopharma for Value Creation The Board and management team regularly evaluate opportunities to enhance shareholder value and are committed to acting in the best interests of
Theravance Biopharma is actively transforming its operations to enhance shareholder value, including a notable cost reduction program that has lowered operating expenses significantly. They recently sold TRELEGY royalty interests for $1.1 billion, contributing to substantial financial gains. The company anticipates generating a non-GAAP profit in the latter half of 2023, while continuing strong sales for YUPELRI. Additionally, the board has changed its composition, promoting diversity and expertise aimed at maximizing shareholder value.
Read more →TBPH▲ +7%on this newsshared move
Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update Increases capital return program to $325 million from $250 million; as of 2/27/23,
Theravance Biopharma, Inc. recently reported its fourth quarter and full year 2022 financial results, highlighting increased shareholder returns and strategic actions to enhance corporate focus. The company has boosted its capital return program to $325 million and expressed confidence in its growth trajectory, particularly regarding YUPELRI, which saw a 25% increase in sales. Additionally, they are moving forward with the Phase 3 clinical trial for ampreloxetine to target patients with neurogenic orthostatic hypotension. With plans to achieve non-GAAP profitability by the latter half of 2023, Theravance aims to create substantial shareholder value.
Read more →TBPHTheravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2022 financial results and provide a business update after...
Theravance Biopharma, Inc. is scheduled to report its fourth quarter and full year 2022 financial results after market close on February 27, 2023. A conference call will be held at 5:00 pm ET on the same day, where further updates will be provided. The company's focus includes delivering medicines that address significant patient needs, exemplified by its FDA-approved product for COPD treatment.
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on Wednesday,...
Theravance Biopharma, Inc. (NASDAQ: TBPH) has announced its participation in the SVB Securities Global Biopharma Conference scheduled for February 15 at 8:00 am ET. Investors will have the opportunity to access a live webcast of the event through Theravance's website. The company remains focused on delivering innovative medicines, including its FDA-approved YUPELRI® for COPD, aimed at improving patient care.
Read more →TBPH▼ -7%on this news
Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets Strategic priorities focused on continued Net Sales growth for YUPELRI (revefenacin) and conduct of the ampreloxetine Phase 3 study (CYPRESS
Theravance Biopharma, Inc. outlined its accomplishments for 2022 and strategic targets for 2023, highlighting success in sales of YUPELRI. The company aims to conduct additional clinical studies and file an NDA for ampreloxetine following productive discussions with the FDA. A significant sale of TRELEGY royalty interests has improved the company's financial position, enabling debt clearance and plans for capital returns. However, continued progress faces several risks related to clinical study timelines and regulatory approvals.
Read more →TBPHTheravance Biopharma, Inc. Announces Final Results of Tender Offer Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced the final results of its Dutch auction tender...
DUBLIN , Nov. 22, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH ) today announced the final results of its Dutch auction tender offer (the "Offer") to purchase up to $95 million of its ordinary shares, par value $0.00001 p
Read more →TBPHTheravance Biopharma, Inc. Announces Preliminary Results of Tender Offer Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced the preliminary results of its Dutch auction...
DUBLIN , Nov. 18, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH ) today announced the preliminary results of its Dutch auction tender offer (the "Offer") to purchase up to $95 million of its ordinary shares, par value $0.0
Read more →TBPHTheravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer Reported another record quarter of YUPELRI (revefenacin) net sales and profitability: $18.7 milli
Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer IRELAND - NOVEMBER 7, 2022 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the
Read more →TBPHAmpreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33 rd International Symposium on the Autonomic Nervous System Totality of Evidence from the Phase 3 Clinical Program Demonstrates Ampreloxet
in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System DUBLIN, November 2, 2022 -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today will present new ampreloxetine data
Read more →TBPHTheravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2022 financial results and provide a business update after market close on...
DUBLIN , Oct. 31, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) will report its third quarter 2022 financial results and provide a business update after market close on Monday, November 7, 2022 . An accompanying conference call and simultaneous webcast will be h
Read more →TBPHTheravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic...
DUBLIN , Oct. 25, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH ) today announced new ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 33 rd International Symposium on the Autonomic N
Read more →TBPHTheravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced a modified Dutch auction tender offer (the...
DUBLIN , Sept. 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH ) today announced a "modified Dutch auction" tender offer (the "Offer") to purchase up to $95 million of its ordinary shares, par value $0.00001 per share (t
Read more →TBPHTheravance Biopharma, Inc. Initiates $250 Million Capital Return Program Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) announced today that its Board of Directors has authorized a $250 ...
DUBLIN , Sept. 19, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH ) announced today that its Board of Directors has authorized a $250 million capital return program consisting of the following three elements: Certain Infor
Read more →TBPHTheravance Biopharma to Present at Upcoming Investor Conferences Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) will be participating in the following Fireside Chats, both of...
DUBLIN , Sept. 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH ) will be participating in the following Fireside Chats, both of which will be webcast: Webcasts of the events may be accessed by visiting Theravance.com, un
Read more →TBPHTheravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update Highest quarter of YUPELRI® (revefenacin) net sales and profitability to date1: $17.2M Q2 2022 sales up 17% from Q2 2021 (implied 35% share)...
DUBLIN , Aug. 4, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH ) today reported financial results for the second quarter of 2022. "The Company has continued to execute on its strategy and, since the first quarter, we have
Read more →TBPHTheravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2022 financial results and provide a business update after market close on...
DUBLIN , July 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) will report its second quarter 2022 financial results and provide a business update after market close on Thursday, August 4, 2022 . An accompanying conference call and simultaneous webcast will be
Read more →TBPHTheravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023 Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced a tender offer (the Offer ) to purchase any and...
DUBLIN , July 26, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH ) today announced a tender offer (the "Offer") to purchase any and all of its outstanding 3.25% Convertible Senior Notes due 2023 (the "Convertible Notes"). A
Read more →TBPHTheravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update Highest quarter of YUPELRI (revefenacin) net sales and profitability to date 1 : $17.2M Q2 2022 sales up 17% from Q2 2
Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update IRELAND - AUGUST 4, 2022 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter of 2022
Read more →TBPHTheravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value Over $1.5 Billion in Potential Total Value,
Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total DUBLIN - July 13, 2022 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH
Read more →TBPH▼ -5.5%on this news
Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update Implied 35% share of YUPELRI (revefenacin) net sales 1 : $15.3M Q1 2022 up 19% from Q1 2021 TRELEGY Q1 2022 global net
Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update - MAY 5, 2022 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter of 2022. "We continu
Read more →TBPH▲ +5.6%on this newsshared move
Theravance Biopharma to Report First Quarter 2022 Financial Results on May 5, 2022 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2022 financial results and provide a business update after market close on...
DUBLIN , May 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) will report its first quarter 2022 financial results and provide a business update after market close on Thursday, May 5, 2022 . An accompanying conference call and simultaneous webcast will be hosted
Read more →TBPH▲ +5.8%on this news
Theravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, at 1:30 pm ET ...
DUBLIN , April 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) will present at the 21 st Annual Needham Virtual Healthcare Conference on Wednesday, April 13 , at 1:30 pm ET ( 10:30 am PT / 6:30 pm IST ). A webcast of the event may be accessed by visiting Thera
Read more →TBPHTheravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH) Results from Study 0170 show a benefit in study
Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH) DUBLIN, April 4, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company
Read more →TBPHTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Implied 35% share of YUPELRI (revefenacin) net sales 1 : $15.3M Q4 2021 up 13% from Q4 2020, $56.7M FY 2
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update - FEBRUARY 23, 2022 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in the Respiratory/Infections Corporate Panel Discussion at the Cowen 42nd Annual Health...
DUBLIN , Feb. 22, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) will participate in the Respiratory/Infections Corporate Panel Discussion at the Cowen 42 nd Annual Health Care Conference on Tuesday, March 8 , at 2:10 pm ET ( 11:10 am PT / 7:10 pm GMT ). A webca
Read more →TBPHTheravance Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022 Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2021 financial results and provide a business update after...
DUBLIN , Feb. 9, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) will report its fourth quarter and full year 2021 financial results and provide a business update after market close on Wednesday, February 23, 2022 . An accompanying conference call and simultaneous
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, at 3:40 ...
DUBLIN , Feb. 2, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) will present at the SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16 , at 3:40 pm ET ( 12:40 pm PT / 8:40 pm GMT ). A webcast of the event may be accessed by visiting
Read more →TBPHJP Morgan Healthcare Conference
Under the safe harbor provisions of the U . S . Private Securities Litigation Reform Act of 1995 , the company cautions investors that any forward - looking statements or projections made by the company are subject to risks and uncertainties that may cause actual results to diffe
Read more →TBPHTheravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today announced enrollment of the first patient in a Phase 4...
DUBLIN , Jan. 10, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH ) today announced enrollment of the first patient in a Phase 4 study of YUPELRI ® (revefenacin) inhalation solution, the first and only once-daily, nebulized
Read more →TBPHTheravance Biopharma to Present at the 40th Annual J.P. Morgan Healthcare Conference Theravance Biopharma, Inc. (NASDAQ: TBPH), a biopharmaceutical company primarily focused on the discovery, development and commercialization of...
DUBLIN , Jan. 5, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines, will present as follows: Webcast of the event may be accessed by visiting
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH), a biopharmaceutical company primarily focused on the discovery, development and commercialization of...
DUBLIN , Nov. 18, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines, will participate in a fireside chat as follows: Webcast of the event may
Read more →TBPHTheravance Biopharma, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update Ø Implied 35% share of YUPELRI (revefenacin) US net sales 1 : $13.8 million, up 7% from Q3 2020 Ø TRELEGY
Theravance Biopharma, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update IRELAND - November 3, 2021 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter of 2021.
Read more →TBPHTheravance Biopharma to Report Third Quarter 2021 Financial Results November 3, 2021 Theravance Biopharma, Inc. (NASDAQ: TBPH), will report its third quarter 2021 financial results and provide a business update after market close on...
DUBLIN , Oct. 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), will report its third quarter 2021 financial results and provide a business update after market close on Wednesday, November 3, 2021 . An accompanying conference call and simultaneous webcast will
Read more →TBPHCONSULTING AGREEMENT Effective
CONSULTING AGREEMENT Effective September 30, 2021 (the "Effective Date"), Bradford J. Shafer ("Consultant") and Theravance Biopharma US, Inc. ("Theravance Biopharma" or the "Company") agree as follows: 1. Services and Payment. Consultant agrees to consult with and advise Ther
Read more →TBPH▼ -15.8%on this news
Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the ...
DUBLIN and SOUTH SAN FRANCISCO, Calif. , Sept, 15, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-se
Read more →TBPH▼ -6.7%on this news· ran to -21% by day 1shared move
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio Implements significant cost reduction program Expects to be sustainably cash flow positive beginning 2H 2022 Investor confe
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio AND SOUTH SAN FRANCISCO, CALIF. - SEPTEMBER 15, 2021 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced strategic actions to focu
Read more →TBPHTheravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis Randomized, double-blind, placebo-controlled study did not meet the prim
Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis IRELAND and SOUTH SAN FRANCISCO, Calif. - August 23, 2021 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company")
Read more →TBPHTheravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update Ø Company reiterates Q3 2021 top-line results timing for ampreloxetine Phase 3 and izencitinib Phase 2b in ulce
Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update - AUGUST 3, 2021 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter of 2021. "We ma
Read more →TBPH▲ +5.6%on this news
Theravance Biopharma to Report Second Quarter 2021 Financial Results on August 3, 2021 Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and...
DUBLIN, Ireland , July 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2021 financial re
Read more →TBPHTheravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ), a diversified biopharmaceutical company primarily focused on the discovery,...
DUBLIN , June 24, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today the pricing of i
Read more →TBPHTheravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares DUBLIN, IRELAND
Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares DUBLIN, IRELAND -June 24, 2021 - Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focused on the discovery, development and co
Read more →TBPHTheravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19 Randomized, double-blind, placebo-controlled study did not meet the
Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due - Randomized, double-blind, placebo-controlled study did not meet the primary endpoint: number of Respiratory Failure-Free Days (RFDs) from randomiz
Read more →TBPHTheravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and...
DUBLIN , May 6, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in an investor event as follows: Webcast
Read more →TBPHTheravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update Ø Company completed enrollment for Phase 2 nezulcitinib (TD-0903, COVID lung hyperinflammation) and Phase 2b ize
Theravance Biopharma, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update IRELAND - may 4, 2021 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter of 2021. "202
Read more →TBPHTheravance Biopharma to Report First Quarter 2021 Financial Results on May 4, 2021 Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and...
DUBLIN , April 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its first quarter 2021 financial results and
Read more →TBPHTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Ø Company's implied 35% share of YUPELRI (revefenacin) net sales 1 : $13.6M Q4 2020, $50.0M FY 20
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update IRELAND - FEBRUARY 23, 2021 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth
Read more →TBPHTheravance Biopharma to Participate in Upcoming Investor Conferences Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and...
DUBLIN , Feb. 10, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in investor events as follows: Webcast
Read more →TBPHTheravance Biopharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 23, 2021 Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and...
DUBLIN , Feb. 9, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its fourth quarter and full year 2020 financia
Read more →TBPHTheravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and...
DUBLIN , Jan. 5, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, will webcast its presentation at the 39 th Annual J.P. Mo
Read more →TBPHTheravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and...
DUBLIN , Nov. 17, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast a presentation as follows: Webcast of the p
Read more →TBPHTheravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update YUPELRI (revefenacin) share of the nebulized COPD market increased to 17.4% through July 2020 (up from 16% in April 202
Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update IRELAND - NOVEMBER 5, 2020 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter ending S
Read more →TBPHTheravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020 Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and...
DUBLIN , Oct. 22, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its third quarter 2020 financial results and
Read more →TBPHCorporate Overview September 2020 THERAVANCE BIOPHARMA , THERAVANCE , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and cer
Forward - looking statements 2 Under the safe harbor provisions of the U . S . Private Securities Litigation Reform Act of 1995 , the company cautions investors that any forward - looking statements or projections made by the company are subject to risks and uncertainties that ma
Read more →TBPHTheravance Biopharma to Present at Upcoming Investor Conferences Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and...
DUBLIN , Sept. 1, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast Management presentations as follows: Webcas
Read more →TBPHTheravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update Ampreloxetine and TD-1473 programs progressing towards three data readouts in 2021 YUPELRI (revefenacin) gained market
Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update IRELAND - AUGUST 6, 2020 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter ending J
Read more →TBPHTheravance Biopharma to Report Second Quarter 2020 Financial Results on August 6, 2020 Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and...
DUBLIN , July 27, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2020 financial results and
Read more →TBPHTheravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ), a diversified biopharmaceutical company primarily focused on the ...
DUBLIN , July 2, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced
Read more →TBPHTheravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903 for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ), a diversified biopharmaceutical company primarily focused on the ...
DUBLIN and SOUTH SAN FRANCISCO, Calif. , June 25, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-sele
Read more →TBPHTheravance Biopharma, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update TD-0903, an investigational lung-selective nebulized Janus kinase inhibitor (JAKi) with the potential to treat Acute Lu
Theravance Biopharma, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update IRELAND - May 6, 2020 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter ended March 3
Read more →TBPHTheravance Biopharma to Report First Quarter 2020 Financial Results on May 6, 2020 Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and...
DUBLIN , April 28, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its first quarter 2020 financial results and
Read more →TBPHTheravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ), a diversified biopharmaceutical company primarily focused on the ...
DUBLIN and SOUTH SAN FRANCISCO, Calif. , April 23, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-sel
Read more →TBPHTheravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ), a diversified biopharmaceutical company primarily focused on the ...
DUBLIN , April 20, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announce
Read more →TBPHTheravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury Clinical Trial Application (CTA) submitted in the United Kingdom for first in human study of T
Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury DUBLIN, IRELAND and SOUTH SAN FRANCISCO, CA - APRIL 9, 2020 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified
Read more →TBPHTheravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes DUBLIN
Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes - March 2, 2020 - Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" and together with its subsidiaries, the "Company"), a diversified biopharmaceutical company primarily focused
Read more →TBPHTheravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update YUPELRI (revefenacin) is realizing strong customer acceptance and market uptake, in partnership with Myl
Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update - February 24, 2020 - Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the fourth quarter
Read more →TBPHTheravance Biopharma Announces Presentations at Upcoming Investor Conferences Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and...
DUBLIN , Feb. 18, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast Management presentations: Webcasts of the p
Read more →TBPHTheravance Biopharma to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020 Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and...
DUBLIN , Feb. 13, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its fourth quarter and full year 2019 financi
Read more →TBPHSUMMARY Overview Theravance Biopharma, Inc. ( Theravance Biopharma ) is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our purp
Biopharma, Inc. ("Theravance Biopharma") is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Our purpose is to create transformational medicines to improve the lives of patients suffering
Read more →TBPHTheravance Biopharma Announces Pricing of Public Offering of Ordinary Shares Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ), a diversified biopharmaceutical company primarily focused on the ...
DUBLIN , Feb. 11, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today
Read more →TBPHTheravance Biopharma Announces Proposed Public Offering of Ordinary Shares Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ), a diversified biopharmaceutical company primarily focused on the ...
DUBLIN , Feb. 10, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today
Read more →TBPHCorporate Presentation January 2020 THERAVANCE , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE are registered trademarks of the Theravance Biopharma group of companies. All third party trademarks used herein a
Forward looking statements 2 Under the safe harbor provisions of the U . S . Private Securities Litigation Reform Act of 1995 , the company cautions investors that any forward - looking statements or projections made by the company are subject to risks and uncertainties that may
Read more →TBPHTheravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and...
DUBLIN , Jan. 7, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast its presentation at the 38 th Annual J.P. Mor
Read more →TBPHTheravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program Topically-Applied, Skin-Selective Pan-JAK Inhibitors Specifically Designed to
Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program Topically-Applied, Skin-Selective Pan-JAK Inhibitors Specifically Designed to Target Pro-Inflammatory Pathways with Minimal Systemic E
Read more →TBPHTheravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced dosing of the first patient in a Phase 2 allergen ...
DUBLIN , Dec. 3, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 allergen challenge study of TD-8236, an investigational, lung-selective inhaled pan-Janus kinase (JA
Read more →TBPHTheravance Biopharma to Present at Two Upcoming Investor Conferences Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in fireside chats at two upcoming investor conferences:...
DUBLIN , Nov. 26, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that management will participate in fireside chats at two upcoming investor conferences: A live broadcast will be available by visiting the Investor Relations section of Theravance
Read more →TBPHTheravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference November 6, 2019 – Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a corporate presentation at the 28th ...
DUBLIN , Nov. 6, 2019 /PRNewswire/ -- November 6, 2019 – Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that management will participate in a corporate presentation at the 28th Annual Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 , at 3:00 p.m. MT
Read more →TBPHTheravance Biopharma, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update Late-stage clinical studies of ampreloxetine and gut-selective oral pan-JAK inhibitor TD-1473 progressing Lung-selectiv
Theravance Biopharma, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update clinical studies of ampreloxetine and gut-selective oral pan-JAK inhibitor TD-1473 progressing inhaled pan-JAK inhibitor TD-8236 progressing to allergen challenge study follow
Read more →TBPHTheravance Biopharma to Report Third Quarter 2019 Financial Results on November 5 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it will release financial results for the...
DUBLIN , Oct. 29, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended September 30, 2019 and provide a business update after market close on Tuesday,
Read more →TBPHTheravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 2019 Cantor Global Healthcare...
DUBLIN , Sept. 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that management will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 , at 7:45 a.m. ET . The conference will take place O
Read more →TBPHThe field allows up to 17 characters.
The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei_EntityFileNum
Read more →TBPHTheravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced initial results, including positive biomarker...
DUBLIN , Sept. 9, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced initial results, including positive biomarker responses, from its Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clin
Read more →TBPHTheravance Biopharma, Inc. (NASDAQ: TBPH) Investor Presentation
Forward Looking Statements Under the safe harbor provisions of the U . S . Private Securities Litigation Reform Act of 1995 , the company cautions investors that any forward - looking statements or projections made by the company are subject to risks and uncertainties that may ca
Read more →TBPHTheravance Biopharma to Present at Two Upcoming Investor Conferences Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in fireside chats at two upcoming investor...
DUBLIN , Aug. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that members of management will participate in fireside chats at two upcoming investor conferences: A live broadcast will be available by visiting the Investor Relations section of
Read more →TBPHTheravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update Late-stage clinical studies of TD-1473 and ampreloxetine progressing Phase 1 results including biomarker data in asthm
Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update Late-stage clinical studies of TD-1473 and ampreloxetine progressing Phase 1 results including biomarker data in asthmatics for lung-selective inhaled pan-JAK inhibitor TD-8236
Read more →TBPHTheravance Biopharma to Report Second Quarter 2019 Financial Results on July 31 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it will release financial results for the...
DUBLIN , July 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended June 30, 2019 and provide a business update prior to market open on Wednesday, J
Read more →TBPHTheravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Oral Presentation at 32nd European Neurology Congress Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today reported new data from the Company's Phase 2 clinical trial ...
DUBLIN , July 22, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today reported new data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) in an
Read more →TBPHTheravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today reported new data from the Company's Phase 2 clinical trial ...
DUBLIN , June 18, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today reported new data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) in a
Read more →TBPHEfficacy, Durability, and Safety of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects With Primary Autonomic Failure Horacio Kaufmann,1 Ita
Efficacy, Durability, and Safety of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects With Primary Autonomic Failure Horacio Kaufmann,1 Italo Biaggioni,2 Krai Chatamra,3 Ashok Panneerselvam,3 Brett H
Read more →TBPHTheravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) and Mylan N.V. (NASDAQ: MYL) ...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , June 14, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL ) ("Mylan") today announced the expansion of the
Read more →TBPHTheravance Biopharma, Inc. (NASDAQ: TBPH) Investor Presentation Evercore ISI Webinar
Forward Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company are subject to risks and uncertainties that may cause ac
Read more →TBPHTheravance Biopharma Appoints Andrew Hindman as Senior Vice President and Chief Financial Officer Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced the appointment of Andrew Hindman as Senior Vice...
DUBLIN , June 4, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced the appointment of Andrew Hindman as Senior Vice President and Chief Financial Officer. Mr. Hindman brings nearly 25 years of life science in
Read more →TBPHTheravance Biopharma Reports Data from Phase 1b Study of TD-1473 in Oral Presentation at Digestive Disease Week (DDW) 2019 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today reported data from the exploratory Phase 1b study of the...
DUBLIN, Ireland , May 21, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today reported data from the exploratory Phase 1b study of the gut-selective pan-Janus kinase (JAK) inhibitor, TD-1473, in an oral presentation at D
Read more →TBPHTheravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) and Mylan N.V. (NASDAQ: MYL) ( Mylan ) today announced the presentation of data...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , May 20, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL ) ("Mylan") today announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-
Read more →TBPHTheravance Biopharma Announces Data from Phase 1b Study of TD-1473 to be Featured in Oral Presentation at Digestive Disease Week (DDW) 2019 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that results from the Company's Phase 1b study of ...
DUBLIN , May 14, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that results from the Company's Phase 1b study of TD-1473 in patients with moderately-to-severely active ulcerative colitis will be the focus
Read more →TBPHTheravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update Late-stage clinical studies of TD-1473 and ampreloxetine underway Phase 1 results including biomarker data in asthmatic
Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update Late-stage clinical studies of TD-1473 and ampreloxetine underway Phase 1 results including biomarker data in asthmatics for lung-selective inhaled pan-JAK inhibitor TD-8236 exp
Read more →TBPHTheravance Biopharma to Report First Quarter 2019 Financial Results on May 7 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it will release financial results for the...
DUBLIN, Ireland , April 30, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended March 31, 2019 and provide a business update after market close on Tue
Read more →TBPHTheravance Biopharma to Present at the 18th Annual Needham Healthcare Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the 18th Annual Needham...
DUBLIN, Ireland , April 2, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that members of management will participate in a fireside chat at the 18 th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 , at 9:20 a.m. ET . The conference
Read more →TBPHTheravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that data from the Company's Phase 2 clinical...
DUBLIN , March 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) have been selected for an oral presentation at the 32nd Euro
Read more →TBPHTheravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced dosing of the first patient in a Phase 2b/3 study ...
DUBLIN , March 12, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2b /3 study of TD-1473 in patients with moderately to severely active ulcerative colitis. TD-1473 is
Read more →TBPHTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update YUPELRI TM (revefenacin) inhalation solution product launch progressing in partnership with Mylan Amprel
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update YUPELRITM (revefenacin) inhalation solution product launch progressing in partnership with Mylan Ampreloxetine and TD-1473 late-stage clinical programs advancing
Read more →TBPHTheravance Biopharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 8th Annual SVB Leerink Global...
DUBLIN , Feb. 21, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that management will participate in a fireside chat at the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 , at 9:00 a.m. ET . The conference will
Read more →TBPHTheravance Biopharma to Report Fourth Quarter and Full Year 2018 Financial Results on February 26 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it will release financial results for the...
DUBLIN , Feb. 19, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended December 31, 2018 and provide a business update after market close on Tuesday, F
Read more →TBPHTheravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced dosing of the first patient in a registrational...
DUBLIN , Jan. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a registrational Phase 3 clinical trial of ampreloxetine (TD-9855) in patients with symptomatic neurogenic or
Read more →TBPHTheravance Biopharma, Inc. (NASDAQ: TBPH) Investor Presentation January 2019 THERAVANCE , the Cross/Star logo, and MEDICINES THAT MAKE A DIFFERENCE are registered trademarks of the Theravance Biopharma group of companies
Forward Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company are subject to risks and uncertainties that may cause ac
Read more →TBPHTheravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced a reduction in workforce to align with its focus...
DUBLIN , Jan. 7, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced a reduction in workforce to align with its focus on continued execution of key strategic programs, and advancement of selected late-stage res
Read more →TBPHTheravance Biopharma to Highlight Innovative Early Research and Clinical Development at R&D Day on December 12 in New York Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) will host an R&D Day from 12:00 p.m. ET to 3:00 p.m. ET on...
DUBLIN , Dec. 4, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") will host an R&D Day from 12:00 p.m. ET to 3:00 p.m. ET on Wednesday , December 12, 2018, in New York City . Theravance Biopharma management and R&D teams wi
Read more →TBPHTheravance Biopharma Announces Closing of Private Placement of $250 Million of 9% Non-Recourse Notes DUBLIN, IRELAND
Theravance Biopharma Announces Closing of Private Placement of $250 Million of 9% Non-Recourse Notes DUBLIN, IRELAND - December 3, 2018 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma and together with its subsidiaries, the Company ) today announced the closing
Read more →TBPHTheravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced dosing of the first subject in a Phase 1 clinical ...
DUBLIN , Nov. 27, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced dosing of the first subject in a Phase 1 clinical trial of TD-8236, a novel, inhaled, lung-selective pan-Janus kinase (JAK) inhibitor which
Read more →TBPHTheravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced dosing of the first patient in a Phase 2 clinical ...
DUBLIN , Nov. 20, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 clinical trial of TD-1473 in patients with Crohn's disease. TD-1473 is a novel, potent, orally admi
Read more →TBPHTheravance Biopharma Highlights Expanded COPD Indication for Trelegy Ellipta in Europe Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) today highlighted that the European Commission authorized an expanded label for...
DUBLIN , Nov. 12, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") today highlighted that the European Commission authorized an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI'), recogn
Read more →TBPHTheravance Biopharma and Mylan Receive FDA Approval for YUPELRI TM (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease YUPELRI (revefenacin) is the first and only once-daily, nebulized bronchodilator appro
Theravance Biopharma and Mylan Receive FDA Approval for YUPELRITM (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease YUPELRI (revefenacin) is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US DUBLIN, IRELAND, HE
Read more →TBPHTheravance Biopharma to Present at the Credit Suisse 27th Annual Healthcare Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will present a corporate overview at the Credit Suisse 27th Annual...
DUBLIN , Nov. 7, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that management will present a corporate overview at the Credit Suisse 27 th Annual Healthcare Conference on Wednesday, November 14, 2018 , at 8:35 a.m. MST . The conference will be h
Read more →TBPHTheravance Biopharma Announces Sale of VIBATIV® (telavancin) to Cumberland Pharmaceuticals Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced the sale of its proprietary antibiotic, VIBATIV®...
DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced the sale of its proprietary antibiotic, VIBATIV ® (telavancin), to Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ), a specialty pharmaceutic
Read more →TBPHTheravance Biopharma, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update PDUFA date for YUPELRI TM (revefenacin) inhalation solution on November 13 TD-1473 and TD-9855 entering late-stage clin
Theravance Biopharma, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update PDUFA date for YUPELRITM (revefenacin) inhalation solution on November 13 TD-1473 and TD-9855 entering late-stage clinical development programs; TD-8236 advancing from research
Read more →TBPHTheravance Biopharma to Report Third Quarter 2018 Financial Results on November 6 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it will release financial results for the...
DUBLIN , Oct. 30, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended September 30, 2018 and provide a business update after market close on Tuesday,
Read more →TBPHTheravance Biopharma Reports Data from TD-1473 Phase 1b Four-Week Study in Oral Late-Breaker Presentation at UEG Week 2018 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today reported the results from the exploratory Phase 1b study of ...
DUBLIN , Oct. 22, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today reported the results from the exploratory Phase 1b study of the gut-selective pan-Janus kinase (JAK) inhibitor TD-1473 in an oral presentation as part
Read more →TBPHTheravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that the results from the Phase 1b study of...
DUBLIN , Oct. 10, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that the results from the Phase 1b study of TD-1473 in patients with moderately-to-severely active ulcerative colitis have been selected for
Read more →TBPHTheravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2018 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that positive new data from multiple studies of...
DUBLIN , Oct. 8, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that positive new data from multiple studies of VIBATIV ® (telavancin) were presented at IDWeek ™ 2018, which was held in San Francisco, CA ,
Read more →TBPHTheravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2018 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that new data on VIBATIV® (telavancin) will be...
DUBLIN , Oct. 1, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that new data on VIBATIV ® (telavancin) will be presented at IDWeek ™ 2018 in San Francisco, CA , on October 3 – 7, 2018. Two presentations w
Read more →TBPHTheravance Biopharma Highlights Positive CHMP Opinion Supporting Expanded COPD Indication for Trelegy Ellipta in Europe Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) today highlighted that the European Medicines Agency's (EMA) Committee for...
DUBLIN , Sept. 24, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") today highlighted that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion supporting the use of Trele
Read more →TBPHTheravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) today announced positive four-week results from a Phase 2 clinical trial of...
DUBLIN , Aug. 1, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") today announced positive four-week results from a Phase 2 clinical trial of TD-9855, an investigational, once-daily norepinephrine and serotonin reuptake inhibitor (NSRI) in
Read more →TBPHTheravance Biopharma, Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update TD-1473 Advancing into Phase 2b/3 Study in Ulcerative Colitis in Fourth Quarter Following Completion of Phase 1b Study
Theravance Biopharma, Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update TD-1473 Advancing into Phase 2b/3 Study in Ulcerative Colitis in Fourth Quarter Following Completion of Phase 1b Study and Successful Dialogues with FDA and EMA TD-1473 Advanci
Read more →TBPHTheravance Biopharma to Report Second Quarter 2018 Financial Results on August 1 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it will release financial results for the...
DUBLIN , July 25, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended June 30, 2018 and provide a business update before market open on Wednesday, Aug
Read more →TBPHTheravance Biopharma Highlights Submission of Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) today highlighted that a regulatory application for once-daily fluticasone...
DUBLIN , May 29, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") today highlighted that a regulatory application for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg) under the proposed brand name Trelegy
Read more →TBPHTheravance Biopharma to Host Key Opinion Leader Event Focused on the Unmet Medical Need in the Treatment of Neurogenic Orthostatic Hypotension Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a key opinion leader event focusing on neurogenic orthostatic hypotension ...
DUBLIN , May 17, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) today announced that it will host a key opinion leader event focusing on neurogenic orthostatic hypotension (nOH) beginning at 12:00 p.m. ET on Thursday , May 24, 2018 in New York City . The event wi
Read more →TBPHTheravance Biopharma to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Chairman and Chief Executive Officer will participate in a fireside ...
DUBLIN , May 10, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that Rick E Winningham, Chairman and Chief Executive Officer will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Healthcare Conference on Thursday, May 17, 2
Read more →TBPHTheravance Biopharma, Inc. Reports First Quarter 2018 Financial Results and Provides Business Update Focusing on Advancement of Highest Priority Programs DUBLIN, IRELAND MAY 8, 2018 Theravance Biopharma, Inc. ( Theravanc
Theravance Biopharma, Inc. Reports First Quarter 2018 Financial Results and Provides Business Update Focusing on Advancement of Highest Priority Programs DUBLIN, IRELAND MAY 8, 2018 Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) today reported
Read more →TBPHTheravance Biopharma to Report First Quarter 2018 Financial Results on
Theravance Biopharma to Report First Quarter 2018 Financial Results on May 8, 2018 DUBLIN, IRELAND May 1, 2018 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it will release financial results for the period ended March 31,
Read more →TBPHTheravance Biopharma Highlights Approval of Expanded Indication in the US for Once-Daily Trelegy Ellipta for Treatment of COPD Patients Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) today highlighted that the US Food and Drug Administration (FDA) has approved an...
DUBLIN , April 25, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") today highlighted that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta. This expanded approval in the US allows Trelegy El
Read more →TBPHTheravance Biopharma Highlights Landmark IMPACT Study Published in NEJM Showing Significant Benefits of Trelegy Ellipta for COPD Patients Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) today highlighted the publication in the New England Journal of Medicine (NEJM) of ...
DUBLIN , April 19, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") today highlighted the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study of Trelegy Ellipta in patients with chronic obstructive pulmona
Read more →TBPHTheravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that new data from studies of VIBATIV®...
DUBLIN , April 17, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that new data from studies of VIBATIV ® (telavancin) will be presented at the 28th European Congress of Clinical Microbiology and Infectiou
Read more →TBPHTheravance Biopharma to Present at the 17th Annual Needham Healthcare Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will present a corporate overview at the 17th Annual Needham...
DUBLIN , March 21, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that members of management will present a corporate overview at the 17 th Annual Needham Healthcare Conference on Wednesday, March 28, 2018 , at 9:00 a.m. ET . The conference will b
Read more →TBPHTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update Multiple Programs Poised to Advance in 2018 DUBLIN, IRELAND FEBRUARY 27, 2018 Theravance Biopharma, Inc.
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update Multiple Programs Poised to Advance in 2018 DUBLIN, IRELAND FEBRUARY 27, 2018 Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) (NASDAQ: TBPH) to
Read more →TBPHTheravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it will release financial results for the...
DUBLIN , Feb. 20, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended December 31, 2017 after market close on Tuesday, February 27, 2018 . An accompa
Read more →TBPHTheravance Biopharma Enters Global Collaboration with Janssen for TD-1473 in Inflammatory Intestinal Diseases Theravance Biopharma Together with Janssen will Jointly Develop and Commercialize TD-1473, a Novel, Potent, Or
Theravance Biopharma Enters Global Collaboration with Janssen for TD-1473 in Inflammatory Intestinal Diseases Theravance Biopharma Together with Janssen will Jointly Develop and Commercialize TD-1473, a Novel, Potent, Orally Administered and Intestinally Restricted pan-Janus Kin
Read more →TBPHTheravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) and Mylan N.V. (NASDAQ, TASE: MYL) ( Mylan ) today announced that the U.S. Food...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Jan. 29, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced that the U.S. Food and Drug Administration (FDA) has accepted for revi
Read more →TBPHInvestor Presentation January 2018 Theravance Biopharma, Inc. (NASDAQ: TBPH) Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act
Investor Presentation January 2018 Theravance Biopharma, Inc. (NASDAQ: TBPH) Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-l
Read more →TBPHTheravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) today highlighted the filing of a supplemental New Drug Application (sNDA) with...
DUBLIN , Nov. 28, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") today highlighted the filing of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) for the use of Trelegy Ellipta, the triple combin
Read more →TBPHTheravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta as Once-Daily Single Inhaler Triple Therapy for the Treatment of COPD Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) today highlighted that the European Commission has granted marketing authorization ...
DUBLIN , Nov. 16, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") today highlighted that the European Commission has granted marketing authorization for Trelegy Ellipta, the triple combination therapy of fluticasone furoate, umeclidinium,
Read more →TBPHTheravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) and Mylan N.V. (NASDAQ, TASE: MYL) ( Mylan ) today announced the submission of a...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Nov. 13, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the submission of a New Drug Application (NDA) to the U.S. Food and Dr
Read more →TBPHTheravance Biopharma, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update Inflection Points for Key Development Programs Anticipated Throughout 2018 Trelegy Ellipta Launch Expected by Year-End
Theravance Biopharma, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update Inflection Points for Key Development Programs Anticipated Throughout 2018 Trelegy Ellipta Launch Expected by Year-End 2017 DUBLIN, IRELAND NOVEMBER 7, 2017 Theravance Biopharm
Read more →TBPHTheravance Biopharma Announces Opening of Company's New Corporate Office in Dublin, Ireland Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) today announced the opening of a new corporate office in Dublin, further...
DUBLIN , Nov. 1, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") today announced the opening of a new corporate office in Dublin , further establishing the Company's presence in Ireland . The Company plans to expand its Dublin employee bas
Read more →TBPHTheravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) and Mylan N.V. (NASDAQ, TASE: MYL) ( Mylan ) today announced the presentation of...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Nov. 1, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the presentation of additional positive efficacy data from the three-mo
Read more →TBPHTheravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR™ Observational Patient Registry at 2017 CHEST Annual Meeting Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that positive preliminary new data from the...
DUBLIN , Oct. 31, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that positive preliminary new data from the Telavancin Observational Use Registry (TOUR ™ ) study were presented at the 2017 CHEST annual me
Read more →TBPHTheravance Biopharma to Report Third Quarter 2017 Financial Results on November 7, 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it will release financial results for the...
DUBLIN , Oct. 30, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended September 30, 2017 after market close on Tuesday, November 7, 2017 . An accompa
Read more →TBPHTheravance Biopharma to Present New Data from Studies of VIBATIV® (telavancin) and Revefenacin (TD-4208) at the 2017 CHEST Annual Meeting Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that data from new studies of VIBATIV®...
DUBLIN , Oct. 24, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that data from new studies of VIBATIV ® (telavancin) and revefenacin (TD-4208) will be presented at the 2017 CHEST annual meeting, being hel
Read more →TBPHTheravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that positive new data from multiple studies of...
DUBLIN , Oct. 9, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that positive new data from multiple studies of VIBATIV ® (telavancin) were presented at IDWeek ™ 2017, which was held in San Diego, CA on Oc
Read more →TBPHTheravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that data from new studies of VIBATIV®...
DUBLIN , Oct. 3, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that data from new studies of VIBATIV ® (telavancin) will be presented at IDWeek ™ 2017, being held in San Diego, CA on October 4 - 8, 2017 .
Read more →TBPHTheravance Biopharma Highlights Positive Headline Results from IMPACT Study of Trelegy Ellipta Announced by GlaxoSmithKline and Innoviva Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) today highlighted that GlaxoSmithKline plc (GSK) and Innoviva, Inc. (Innoviva)...
DUBLIN , Sept. 20, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") today highlighted that GlaxoSmithKline plc (GSK) and Innoviva, Inc. (Innoviva) have reported positive headline results from the landmark Phase 3 IMPACT study of Trelegy Ell
Read more →TBPHTheravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) today highlighted that the US Food and Drug Administration (FDA) has approved...
DUBLIN , Sept. 19, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") today highlighted that the US Food and Drug Administration (FDA) has approved Trelegy Ellipta, the triple combination therapy of fluticasone furoate, umeclidinium, and vila
Read more →TBPHTheravance Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will present a corporate overview at the Cantor Fitzgerald...
DUBLIN , Sept. 19, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that members of management will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2017 at 9:10 a.m. ET . The conference wi
Read more →TBPHTheravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta (Closed Triple) Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) today highlighted that GlaxoSmithKline plc (GSK) and Innoviva, Inc. (Innoviva)...
DUBLIN, Ireland , Sept. 18, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") today highlighted that GlaxoSmithKline plc (GSK) and Innoviva, Inc. (Innoviva) have received a positive opinion from the European Medicines Agency's (EMA) Committe
Read more →TBPHTheravance Biopharma to Present at the Morgan Stanley 15th Annual Global Healthcare Conference heravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the Morgan Stanley 15th...
DUBLIN , Sept. 5, 2017 /PRNewswire/ --Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that members of management will participate in a fireside chat at the Morgan Stanley 15th Annual Global Healthcare Conference on Tuesday, September 12, 2017 at 8:00 a.m. ET . The conf
Read more →TBPHInvestor Presentation August 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH) Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act
Investor Presentation August 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH) Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-lo
Read more →TBPHTheravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis Evidence of Localized Target Engagement after Four Weeks of Treatment Minimal System
Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis Evidence of Localized Target Engagement after Four Weeks of Treatment Minimal Systemic Exposure No Evidence of Systemic Immunosuppression or
Read more →TBPHTheravance Biopharma, Inc. Reports Second Quarter 2017 Financial Results and Provides Business Update Meaningful Clinical Readouts Underpin Progress in Key Programs Additional Milestones Anticipated in Remainder of 2017
Theravance Biopharma, Inc. Reports Second Quarter 2017 Financial Results and Provides Business Update Meaningful Clinical Readouts Underpin Progress in Key Programs Additional Milestones Anticipated in Remainder of 2017 and 2018 DUBLIN, IRELAND AUGUST 8, 2017 Theravance Biopha
Read more →TBPHTheravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis Improvements in Symptoms and Normalized Gastric Emptying Demonstrated in both Diabetic a
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis Improvements in Symptoms and Normalized Gastric Emptying Demonstrated in both Diabetic and Idiopathic Gastroparesis Patients DUBLIN, IRELAND, Augu
Read more →TBPHTheravance Biopharma to Report Second Quarter 2017 Financial Results and Business Update on August 8, 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it will release financial results for the...
DUBLIN , Aug. 1, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended June 30, 2017 after market close on Tuesday, August 8, 2017 . An accompanying co
Read more →TBPHTheravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President of Corporate Development and Strategy Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced the appointment of Shehnaaz Suliman, MD, to the...
DUBLIN , July 31, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced the appointment of Shehnaaz Suliman , MD, to the position of Senior Vice President, Corporate Development and Strategy. Dr. Suliman brings m
Read more →TBPHTheravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) and Mylan N.V. (NASDAQ, TASE: MYL) ( Mylan ) today announced positive results from ...
DUBLIN, HERTFORDSHIRE, England and PITTSBURGH , July 19, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced positive results from a 12-month Phase 3 safety study of revefenacin (TD-
Read more →TBPHNew Data Highlighting in vitro Potency Advantages for VIBATIV® (telavancin) Against Difficult-to-Treat MRSA and MSSA Pathogens Reported at ASM Microbe 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced the presentation of positive new data from...
DUBLIN , June 5, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced the presentation of positive new data from multiple studies of VIBATIV ® (telavancin), the Company's proprietary FDA-approved antibiotic. Stu
Read more →TBPHTheravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) and Mylan N.V. (NASDAQ, TASE: MYL) ( Mylan ) today announced the presentation of...
DUBLIN and HERTFORDSHIRE, United Kingdom and PITTSBURGH , May 23, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the presentation of additional efficacy and safety data from the
Read more →TBPHTheravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) and Mylan N.V. (NASDAQ, TASE: MYL) ( Mylan ) today announced that data from...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , May 17, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced that data from several studies of revefenacin (TD-4208) will be present
Read more →TBPHScript used in the previously announced Theravance Biopharma, Inc. conference call held
Script used in the previously announced Theravance Biopharma, Inc. conference call held May 9, 2017 Theravance Biopharma 1Q 2017 Financial Results Conference Call May 9, 2017 2:00 p.m. PT/5:00 p.m. ET Alex Dobbin, Head of Investor Relations Good afternoon, everyone, and than
Read more →TBPHTheravance Biopharma, Inc. Reports First Quarter 2017 Financial Results and Provides Business Update Key Program Milestones Anticipated in Remainder of 2017 and 2018 DUBLIN
Theravance Biopharma, Inc. Reports First Quarter 2017 Financial Results and Provides Business Update Key Program Milestones Anticipated in Remainder of 2017 and 2018 DUBLIN, May 9, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Comp
Read more →TBPHTheravance Biopharma to Report First Quarter 2017 Financial Results on May 9, 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it will release financial results for the...
DUBLIN , May 2, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended March 31, 2017 after market close on Tuesday, May 9, 2017 . An accompanying confe
Read more →TBPHTheravance Biopharma to Present at the Deutsche Bank 42nd Annual Health Care Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will present a corporate overview at the Deutsche Bank 42nd...
DUBLIN , April 27, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that members of management will present a corporate overview at the Deutsche Bank 42nd Annual Health Care Conference on Thursday, May 4, 2017 at 8:00 a.m. ET . The conference will b
Read more →TBPHNew Data for VIBATIV® (telavancin) Reported in Several Presentations at ECCMID 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced the presentation of positive new data from...
DUBLIN , April 25, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced the presentation of positive new data from several studies of VIBATIV ® ( telavancin), the Company's proprietary FDA-approved antibiotic. S
Read more →TBPHTheravance Biopharma Reports Positive Clinical Response Rates for Patients in TOUR™ Observational Patient Registry in Several Presentations at ECCMID 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that new preliminary data from the ongoing...
DUBLIN , April 24, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that new preliminary data from the ongoing Telavancin Observational Use Registry (TOUR ™ ) study are the focus of three poster presentation
Read more →TBPHTheravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin), Including Preliminary Results from TOUR™ Observational Patient Registry, at 2017 ECCMID Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that data from new studies of VIBATIV®...
DUBLIN , April 18, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that data from new studies of VIBATIV ® (telavancin) will be presented at the 27th European Congress of Clinical Microbiology and Infectiou
Read more →TBPHTheravance Biopharma to Present at the 16th Annual Needham Healthcare Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Chairman and Chief Executive Officer, will present a corporate...
DUBLIN , March 28, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that Rick E Winningham, Chairman and Chief Executive Officer, will present a corporate overview at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017 , at 1:40
Read more →TBPHTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update Key Program Milestones Anticipated in 2017 and 2018 DUBLIN
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update Key Program Milestones Anticipated in 2017 and 2018 DUBLIN, Feb. 27, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the
Read more →TBPHTheravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced the presentation of positive clinical data for...
DUBLIN , Feb. 17, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced the presentation of positive clinical data for TD-1473, a novel, potent, and orally administered pan-Janus kinase (JAK) inhibitor designed t
Read more →TBPHTheravance Biopharma to Report Fourth Quarter and Full Year 2016 Financial Results on February 27, 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it will release financial results for the...
DUBLIN , Feb. 15, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended December 31, 2016 after market close on Monday, February 27, 2017 . An accompan
Read more →TBPHTheravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it will highlight clinical data on TD-1473,...
DUBLIN , Feb. 13, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that it will highlight clinical data on TD-1473, a novel, potent, and orally administered pan-Janus kinase (JAK) inhibitor designed to be in
Read more →TBPHTheravance Biopharma to Present at the Leerink Partners 6th Annual Global Healthcare Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the Leerink Partners 6th...
DUBLIN , Feb. 2, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that members of management will participate in a fireside chat at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 2:00 p.m. ET . The con
Read more →TBPHTheravance Biopharma Reports New Data from Ongoing TOUR™ Observational Patient Registry in Oral Presentation at SCCM Critical Care Congress Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today reported new interim data from the Company's ongoing...
DUBLIN , Jan. 23, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today reported new interim data from the Company's ongoing Telavancin Observational Use Registry (TOUR ™ ) study in an oral presentation at the Society of C
Read more →TBPHTheravance Biopharma to Present New Data from Ongoing TOUR™ Observational Patient Registry at SCCM Critical Care Congress Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that new interim data from the Company's ongoing...
DUBLIN , Jan. 17, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that new interim data from the Company's ongoing Telavancin Observational Use Registry (TOUR ™ ) study will be the focus of an oral presenta
Read more →TBPHInvestor Presentation January 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH) Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act
Investor Presentation January 2017 Theravance Biopharma, Inc. (NASDAQ: TBPH) Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-l
Read more →TBPHTheravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that the U.S. Food and Drug Administration (FDA)...
DUBLIN , Dec. 6, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to velusetrag (TD-5108) for the treatment of symptoms ass
Read more →TBPHTheravance Biopharma to Present at the 28th Annual Piper Jaffray Healthcare Conference Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the 28th Annual Piper...
DUBLIN , Nov. 22, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced today that members of management will participate in a fireside chat at the 28 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016 at 10:00 a.m. ET . The conference
Read more →TBPHTheravance Biopharma Highlights Filing of U.S. New Drug Application for the Closed Triple in COPD by GlaxoSmithKline and Innoviva Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma ) today announced that GlaxoSmithKline plc (GSK) and Innoviva, Inc. (Innoviva) have...
DUBLIN , Nov. 21, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma") today announced that GlaxoSmithKline plc (GSK) and Innoviva, Inc. (Innoviva) have filed a New Drug Application (NDA) in the U.S. for the Closed Triple (the combination of fl
Read more →TBPHTheravance Biopharma, Inc. Reports Third Quarter 2016 Financial Results and Provides Business Update DUBLIN
Theravance Biopharma, Inc. Reports Third Quarter 2016 Financial Results and Provides DUBLIN, Nov. 8, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today reported financial results for the third quarter ended September 30,
Read more →TBPHTheravance Biopharma Presents Interim Data from Ongoing Telavancin Observational Use Registry (TOUR™) at IDWeek™ 2016 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced the presentation of interim data from the...
DUBLIN , Oct. 31, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced the presentation of interim data from the Company's ongoing Telavancin Observational Use Registry (TOUR ™ ) study. TOUR is designed to asses
Read more →TBPHTheravance Biopharma Announces Pricing of Public Offerings of 3,850,000 Ordinary Shares and $200 Million of 3.25% Convertible Senior Notes due 2023 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced the pricing of concurrent underwritten public...
DUBLIN , Oct. 27, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) ("Theravance Biopharma" or the "Company") today announced the pricing of concurrent underwritten public offerings of 3,850,000 ordinary shares (the "Shares") at a price to the public of $26.00 per s
Read more →TBPHTheravance Biopharma Announces Proposed Public Offerings of $100 Million of Ordinary Shares and $150 Million of Convertible Senior Notes DUBLIN
Theravance Biopharma Announces Proposed Public Offerings of $100 Million of Ordinary Shares and $150 Million of Convertible Senior Notes DUBLIN, Oct. 26, 2016 Theravance Biopharma, Inc. (NASDAQ: TBPH) ( Theravance Biopharma or the Company ) today announced that it intends to com
Read more →TBPHTheravance Biopharma Announces Positive Results Including Biomarker Data from Phase 1 Multiple-Ascending Dose Study of TD-0714, an Inhibitor of Neprilysin (NEP) Study Findings Consistent with Single-Ascending Dose (SAD)
Theravance Biopharma Announces Positive Results Including Biomarker Data from Phase 1 Multiple-Ascending Dose Study of TD-0714, an Inhibitor of Neprilysin (NEP) Study Findings Consistent with Single-Ascending Dose (SAD) Data, Demonstrating Sustained Target Engagement, Low Levels
Read more →TBPHTheravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Revefenacin Meets Primary Efficacy Endp
Theravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Revefenacin Meets Primary Efficacy Endpoint and is Shown to be Well-Tolerated in Both Studies; Twe
Read more →TBPHInvestor Presentation September 2016 Theravance Biopharma, Inc. (NASDAQ: TBPH) Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform A
Investor Presentation September 2016 Theravance Biopharma, Inc. (NASDAQ: TBPH) Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward
Read more →TBPHGI-Targeted JAK Inhibition for Ulcerative Colitis Dr. Brett Haumann Chief Medical Officer Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that
GI-Targeted JAK Inhibition for Ulcerative Colitis Dr. Brett Haumann Chief Medical Officer Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the
Read more →TBPHTheravance Biopharma Announces Closing of Public Offering of Its Ordinary Shares DUBLIN, IRELAND--(Marketwired
Theravance Biopharma Announces Closing of Public Offering of Its Ordinary Shares DUBLIN, IRELAND--(Marketwired - May 4, 2016) - Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it has closed the sale of its previously announced underwritten public offering of 5,479
Read more →TBPHTheravance Biopharma Announces Proposed Public Offering of its Ordinary Shares Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it intends to offer, subject to market conditions, 4,250,000 ordinary shares i
Theravance Biopharma Announces Proposed Public Offering of its Ordinary Shares Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it intends to offer, subject to market conditions, 4,250,000 ordinary shares in an underwritten public offering. Theravance Biopharma als
Read more →TBPHCowen and Company 36th Annual Health Care Conference March 2016 Theravance Biopharma, Inc. (NASDAQ: TBPH) Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Sec
Cowen and Company 36th Annual Health Care Conference March 2016 Theravance Biopharma, Inc. (NASDAQ: TBPH) Cautionary Statement Regarding Forward-Looking Statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions
Read more →TBPHInvestor Presentation January 2016 Theravance Biopharma, Inc. (NASDAQ: TBPH) Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-
Investor Presentation January 2016 Theravance Biopharma, Inc. (NASDAQ: TBPH) Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company are s
Read more →TBPHWOODFORD INVESTMENT MANAGEMENT TO MAKE $55
WOODFORD INVESTMENT MANAGEMENT TO MAKE $55 MILLION DIRECT INVESTMENT IN THERAVANCE BIOPHARMA ORDINARY SHARES DUBLIN, Ireland, Oct. 26, 2015 Theravance Biopharma, Inc. (NASDAQ: TBPH) (Theravance Biopharma) today announced that it has entered into a definitive purchase agreement w
Read more →TBPHInvestor Presentation September 2015 Theravance Biopharma, Inc. (NASDAQ: TBPH) THERAVANCE , the Cross?Star logo, VIBA TIV and MEDICINES THAT MAKE A DIFFERENCE are registered trademarks of the Theravance Biopharma group o
Most Common Adverse Reactions The most common adverse reactions (greater than or equal to 10% of patients treated with VIBATIV) were diarrhea, taste disturbance, nausea, vomiting, and foamy urine. Full Prescribing Information, including Boxed Warning and Medication Guide in the U
Read more →TBPHInvestor Relations Presentation August 2015 Theravance Biopharma, Inc. (NASDAQ: TBPH) Rick E Winningham, Chief Executive Officer Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 19
Excludes nebulized short-acting beta agonists. IMS expressly reserves all rights, including rights of copying, distribution and republication Enduring Patient Niche and Significant Market Opportunity Unmet Need for Nebulized LAMA Therapy Once-daily LAMAs are first-line therapy fo
Read more →TBPHWedbush PacGrow Healthcare Conference
Most Common Adverse Reactions The most common adverse reactions (greater than or equal to 10% of patients treated with VIBATIV) were diarrhea, taste disturbance, nausea, vomiting, and foamy urine. Full Prescribing Information, including Boxed Warning and Medication Guide in the U
Read more →TBPHTheravance Biopharma, Inc. (NASDAQ: TBPH) Rick E Winningham Chief Executive Officer Bank of America Merrill Lynch 2015 Health Care Conference Cautionary Statement Regarding Forward-Looking Statements Under the safe harbo
Most Common Adverse Reactions The most common adverse reactions (greater than or equal to 10% of patients treated with VIBATIV) were diarrhea, taste disturbance, nausea, vomiting, and foamy urine. Full Prescribing Information, including Boxed Warning and Medication Guide in the U
Read more →Competitive Position
How TBPH ranks across every disease it competes inCompetitive Position is a premium feature
See how TBPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial